View Older Stories View More Recent Stories
-
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
-
Eli Lilly (LLY) PT Raised to $942 at Guggenheim
-
FDA approves updated dosing for Lilly's Kisunla Alzheimer's treatment
-
Eli Lilly & Co. (LLY) call put ratio 9.5 calls to 1 put with a focus on a spreader of July 850, and 960 calls
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
-
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform
-
Eli Lilly & Co. (LLY) announced FDA approval of updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients
-
Chardan Comments on iBio, Inc. (IBIO)
-
Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital on Eli Lilly (LLY): 'Is It Time to BELIEVE?'
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.8% Yield
-
Evercore ISI Reiterates In Line Rating on Eli Lilly (LLY)
-
BMO Capital: 'Eli Lilly (LLY) Metabolic Portfolio Shows New Legs at ADA Event'
-
Truist Reiterates Buy Rating on Eli Lilly (LLY) Following OFG Presentation at ADA
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
GLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) to Acquire VERV; Bernstein: 'We Like the Deal'
-
Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP
-
Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR
-
Eli Lilly & Co. (LLY) In Advanced Talks To Buy Verve For Up To $1.3bln- FT
-
Bernstein: 'Zepbound Continues to Propel Eli Lilly (LLY)'
-
Eli Lilly & Co. (LLY) to offer all approved doses of Zepbound single-dose vials through LillyDirect Self Pay Pharmacy Solutions
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY) Ahead of ADA 2025
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Citi on Hims and Hers (HIMS): 'If HIMS does end up partnering with LLY, in our view it would signal that HIMS is “throwing in the towel” on compounded GLP-1s'
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
EMA says Ozempic, Wegovy may cause rare eye condition
-
TD Cowen Revisits Eli Lilly's (LLY) Surpass-CVOT Expectations, Lowers Stock PT
-
Erste Group Downgrades Eli Lilly (LLY) to Hold
-
Morgan Stanley weighs in on Eli Lilly (LLY) into SURPASS-CVOT phrase 3 data
-
Wegovy Use Up 50% Among Us Teens - Reuters
-
Eli Lilly & Co. (LLY) presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer
-
Eli Lilly & Co. (LLY) announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics
-
What can get the U.S. large-cap pharma sector to work?
-
Eli Lilly & Co. (LLY) gives presentation highlights for 2025 ASCO
-
Morgan Stanley weighs in on Eli Lilly (LLY) following Cigna GLP-1 news
-
Lilly (LLY) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
-
Truist: 'we share some interesting takeaways from the ruling that could provide a read through on the Wegovy/Ozempic case'
-
Bernstein: 'Softer Week for Total Scripts, but Eli Lilly (LLY) Still Gains Share'
